## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.9% in lower entry zone (4.0-10.0%), top 9% cross-sectional ranking. Short-term MRS_5 (4.4%) confirms momentum alignment. Strong momentum (+1.6% 5-day acceleration). Outperforming sector by 9.2%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($76.08)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Cooper Companies (COO) Margin Decline Tests Bullish 21% Earnings Growth Narrative**
- Source: Simply Wall Street | 20251205T234210 | Somewhat-Bearish | Relevance: 100%
- Cooper Companies (COO) reported Q4 FY 2025 revenues of $1.1 billion and EPS of $0.43, with full-year revenues of $4.1 billion and EPS of $1.87. Despite strong projected earnings growth of 21.4% annually, the company's net income and margins have recently slipped, contrasting with analyst expectations for margin expansion. This disparity, coupled with a high P/E ratio and moderate revenue growth, raises questions about the sustainability of its bullish outlook.

**2. COOPER COMPANIES, INC. SEC 10-K Report**
- Source: TradingView | 20251205T214029 | Somewhat-Bearish | Relevance: 100%
- The Cooper Companies, Inc. has released its annual Form 10-K report, detailing financial performance including net sales of $4,092.4 million and a net income of $374.9 million, alongside strategic initiatives such as recent acquisitions and capital management. The report also highlights future outlooks focused on market penetration and product development, while addressing significant challenges and risks like market volatility, international operations, and supply chain disruptions.

**3. CooperCompanies (COO) Stock Trades Up, Here Is Why**
- Source: Finviz | 20251205T170810 | Bullish | Relevance: 100%
- Shares of CooperCompanies (NASDAQ:COO) jumped 7.6% after the company reported better-than-expected third-quarter 2025 results and provided an upbeat earnings forecast for the upcoming fiscal year. Revenue grew 4.6% to $1.07 billion, meeting estimates, while adjusted earnings per share of $1.15 beat consensus by 3.2%. The company's guidance for fiscal year 2026 also projected adjusted earnings per share of $4.53, exceeding analyst expectations.

**4. COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises**
- Source: TradingView | 20251205T140801 | Bullish | Relevance: 100%
- The Cooper Companies, Inc. (COO) exceeded Q4 fiscal 2025 earnings and sales estimates, driven by strong MyDay contact lens adoption and other operational improvements. The company's revenues reached $1.065 billion, with significant growth in both CooperVision and CooperSurgical segments. COO also provided an optimistic outlook for fiscal 2026, forecasting continued revenue growth and increased EPS, despite facing challenges like gross margin pressure and regional risks.

**5. Why Did Cooper Companies Jump 13%? Strong Q4 and Shareholder Review Lift Sentiment**
- Source: Tokenist | 20251205T134111 | Bullish | Relevance: 100%
- Cooper Companies' shares surged 13.33% following better-than-expected Q4 fiscal 2025 results and the announcement of a strategic review to boost shareholder value. This review comes after pressure from activist investors and will focus on improving performance, expanding market share, and enhancing operational efficiency. The company also provided an optimistic outlook for fiscal 2026, forecasting higher revenue and EPS.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Stifel | $95 | $85 | +12% |
| 2025-12-05 | Piper Sandler | $94 | $83 | +13% |
| 2025-12-05 | Wells Fargo | $82 | $72 | +14% |
| 2025-12-05 | JP Morgan | $78 | $66 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Stifel | reit | Buy |
| 2025-12-05 | Piper Sandler | reit | Overweight |
| 2025-12-05 | Wells Fargo | main | Equal-Weight |
| 2025-12-05 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 7 ($0.91M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Analyst sentiment positive (7 raises, avg +14%). Insider buying signal ($0.9M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.4B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 16.5 |
| Current P/E | 18.1 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 5.2% to 6.9% (+1.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 4.4% confirms short-term momentum alignment. AM_20 at 9.3% shows strong absolute momentum above own 20MA. Outperforming sector by 9.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. Elevated volume (2.3x 20MA), institutional activity likely. OFD pattern: -FTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.87% (CS: 91) | Strong |
| RSI_14 | 73.0 | Overbought |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.129x | Above |
| vs SMA200 | 1.087x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $81.40
- **Stop Loss:** $76.08 (6.5% risk)
- **Target:** $89.38 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $7,570.20
- **Portfolio %:** 7.57%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*